News Column

BRIEF: Oncothyreon stock sinks on disappointing clinical study results

August 19, 2014

The Seattle Times



Aug. 19--The stock of Seattle biotechnology company Oncothyreon sank 48 cents, or 17.3 percent, to $2.30 Tuesday after it said that its experiment cancer therapy, tecemotide, failed in a clinical study in Japan to improve overall survival in patients with non-small cell lung cancer.

Wedbush analysts expect Oncothyreon partner Merck to discontinue the tecemotide program because of the lack of clinical benefit. Tecemotide was designed to work by stimulating the body's immune system so that it could identify and destroy cancer cells.

___

(c)2014 The Seattle Times

Visit The Seattle Times at www.seattletimes.com

Distributed by MCT Information Services


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Seattle Times (WA)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters